RxDoctor Payments Data

David Quon, MD

Ophthalmology · Monterey Park, CANPI 1134216559

Payments from drug & device makers

$4,459in general payments, 2019–2025

Across 233 payments — averaging $19.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$825
  • Boehringer Ingelheim$791
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$516
  • Bayer$513
  • GSK$255
  • Merck$242
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$4,459100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,459 in reported general payments places this provider in the 70th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$111,669
Medicare patients
269
Services billed
858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost158$57,866
CombiganBrimonidine Tartrate/Timolol126$38,442
XiidraLifitegrast33$35,483
RestasisCyclosporine14$15,258
Cyclosporine13$9,689
TobradexTobramycin/Dexamethasone23$6,071
VascepaIcosapent Ethyl11$5,897
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol25$3,949
Acetazolamide ErAcetazolamide23$1,238
MoxifloxacinMoxifloxacin Hcl67$1,194
Tobramycin-DexamethasoneTobramycin/Dexamethasone30$1,082
Latanoprost173$699
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha37$440
Azelastine Hcl28$260
Timolol Maleate14$185

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis$11$111,566298 claims
Bausch & Lomb Americas Inc.Xiidra$23$35,48333 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Monterey Park

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →